U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H12O6
Molecular Weight 336.295
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DICUMAROL

SMILES

OC1=C(CC2=C(O)C3=CC=CC=C3OC2=O)C(=O)OC4=CC=CC=C14

InChI

InChIKey=DOBMPNYZJYQDGZ-UHFFFAOYSA-N
InChI=1S/C19H12O6/c20-16-10-5-1-3-7-14(10)24-18(22)12(16)9-13-17(21)11-6-2-4-8-15(11)25-19(13)23/h1-8,20-21H,9H2

HIDE SMILES / InChI

Molecular Formula C19H12O6
Molecular Weight 336.295
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: https://www.ncbi.nlm.nih.gov/mesh/68001728

Dicumarol is an coumarin-like compound found in sweet clover. It is used as oral anticoagulant and acts by inhibiting the hepatic synthesis of vitamin K-dependent coagulation factors (prothrombin and factors VII, IX, and X). It results in decresed prothrombin levels and a decrease in the amount of thrombin generated and bound to fibrin. This reduces the thrombogenicity of clots. Dicumarol is also used in biochemical experiments as an inhibitor of reductases.

Originator

Curator's Comment: Campbell, H.A. & Link, K.P. (1941) Studies on the hemorrhagic sweet clover disease. IV. The isolation and crystallization of the hemorrhagic agent. Journal of Biological Chemistry, 138, 21–33.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
2.0 µM [IC50]
10.0 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
DICUMAROL

Approved Use

For decreasing blood clotting. Often used along with heparin for treatment of deep vein thrombosis.

Launch Date

-8.0222401E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
20 μg/mL
6 mg/kg single, intravenous
dose: 6 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DICUMAROL plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
521 μg × h/mL
6 mg/kg single, intravenous
dose: 6 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DICUMAROL plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
12.84 h
6 mg/kg single, intravenous
dose: 6 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DICUMAROL plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
0.03%
6 mg/kg single, intravenous
dose: 6 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DICUMAROL plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
Doses

Doses

DosePopulationAdverse events​
200 mg 1 times / day steady, oral
Highest studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
unhealthy, 59.8+15.3 years
n = 71
Health Status: unhealthy
Age Group: 59.8+15.3 years
Sex: M+F
Population Size: 71
Sources:
2100 mg single, oral
Overdose
Dose: 2100 mg
Route: oral
Route: single
Dose: 2100 mg
Sources:
unknown
n = 1
Health Status: unknown
Population Size: 1
Sources:
Disc. AE: Distended blood vessels...
AEs leading to
discontinuation/dose reduction:
Distended blood vessels (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Distended blood vessels 1 patient
Disc. AE
2100 mg single, oral
Overdose
Dose: 2100 mg
Route: oral
Route: single
Dose: 2100 mg
Sources:
unknown
n = 1
Health Status: unknown
Population Size: 1
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Unusual gastrointestinal reaction to bishydroxycoumarin(Dicumarol).
1968 Jul
Urinary tract complications of anticoagulation therapy; "pseudotumour" of the kidney.
1968 Mar
Intraocular hemorrhage and blindness associated with systemic anticoagulation.
1972 Jun 5
Activation and deactivation of quinones catalyzed by DT-diaphorase. Evidence for bioreductive activation of diaziquone (AZQ) in human tumor cells and detoxification of benzene metabolites in bone marrow stroma.
1990
[Fatal cerebral hemorrhage caused by overdose of dicumarol, report of a case].
1992 Feb
Reduction of chromium(VI) to chromium(V) by rat liver cytosolic and microsomal fractions: is DT-diaphorase involved?
1992 Jul
Aspirin-like drugs can protect human T lymphocytes against benzoquinone cytotoxicity: evidence for a NAD(P)H:quinone reductase-dependent mechanism.
1995
Molecular mechanisms of tirapazamine (SR 4233, Win 59075)-induced hepatocyte toxicity under low oxygen concentrations.
1995 Apr
Discovery of novel, non-peptide HIV-1 protease inhibitors by pharmacophore searching.
1996 May 10
Roles of DT diaphorase in the genotoxicity of nitroaromatic compounds in human and fish cell lines.
1997 Oct 10
The role of NAD(P)H:quinone oxidoreductase in quinone-mediated p21 induction in human colon carcinoma cells.
1997 Oct 15
Fulminant hepatic failure associated with dicoumarol therapy.
1998 Feb
Chromium (VI)-induced cytotoxicity to osteoblast-derived cells.
1999 Dec
Copper neurotoxicity is dependent on dopamine-mediated copper uptake and one-electron reduction of aminochrome in a rat substantia nigra neuronal cell line.
2001 Apr
Transient activation of Jun N-terminal kinases and protection from apoptosis by the insulin-like growth factor I receptor can be suppressed by dicumarol.
2001 Jun 1
P53 hot-spot mutants are resistant to ubiquitin-independent degradation by increased binding to NAD(P)H:quinone oxidoreductase 1.
2003 Dec 9
Dicoumarol: a unique microtubule stabilizing natural product that is synergistic with Taxol.
2003 Mar 15
Dicumarol inhibition of NADPH:quinone oxidoreductase induces growth inhibition of pancreatic cancer via a superoxide-mediated mechanism.
2003 Sep 1
Geomorphological evolution and environmental reclamation of Fusaro Lagoon (Campania Province, southern Italy).
2004 Apr
Treatment of pancreatic cancer cells with dicumarol induces cytotoxicity and oxidative stress.
2004 Jul 1
JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells.
2004 May 1
Environmental pollutant and potent mutagen 3-nitrobenzanthrone forms DNA adducts after reduction by NAD(P)H:quinone oxidoreductase and conjugation by acetyltransferases and sulfotransferases in human hepatic cytosols.
2005 Apr 1
Enhanced cytotoxicity of bioreductive antitumor agents with dimethyl fumarate in human glioblastoma cells.
2005 Feb
Arsenite pretreatment enhances the cytotoxicity of mitomycin C in human cancer cell lines via increased NAD(P)H quinone oxidoreductase 1 expression.
2006 Aug 1
Molecular cloning of a novel type of rat cytoplasmic 17beta-hydroxysteroid dehydrogenase distinct from the type 5 isozyme.
2006 Jun
[Proteus penneri].
2006 Oct
Capsaicin induces heme oxygenase-1 expression in HepG2 cells via activation of PI3K-Nrf2 signaling: NAD(P)H:quinone oxidoreductase as a potential target.
2007 Dec
Role of NAD(P)H:quinone oxidoreductase 1 on tumor necrosis factor-alpha-induced migration of human vascular smooth muscle cells.
2007 Nov 1
The role of aryl hydrocarbon receptor in regulation of enzymes involved in metabolic activation of polycyclic aromatic hydrocarbons in a model of rat liver progenitor cells.
2009 Jul 15
Low levels of the air pollutant 1-nitropyrene induce DNA damage, increased levels of reactive oxygen species and endoplasmic reticulum stress in human endothelial cells.
2009 Jul 28
Cost-effective interrogation of single nucleotide polymorphisms using the mismatch amplification mutation assay and capillary electrophoresis.
2010 Dec
Finding new enzymes from bacterial physiology: a successful approach illustrated by the detection of novel oxidases in Marinomonas mediterranea.
2010 Mar 5
Biochemical mechanism of caffeic acid phenylethyl ester (CAPE) selective toxicity towards melanoma cell lines.
2010 Oct 6
Inhibition of renal NQO1 activity by dicoumarol suppresses nitroreduction of aristolochic acid I and attenuates its nephrotoxicity.
2011 Aug
Discovery of 2-(4-methylfuran-2(5H)-ylidene)malononitrile and thieno[3,2-b]thiophene-2-carboxylic acid derivatives as G protein-coupled receptor 35 (GPR35) agonists.
2011 Oct 27
NAD(P)H:quinone oxidoreductase 1 (NQO1) competes with 20S proteasome for binding with C/EBPα leading to its stabilization and protection against radiation-induced myeloproliferative disease.
2012 Dec 7
Stress-induced NQO1 controls stability of C/EBPα against 20S proteasomal degradation to regulate p63 expression with implications in protection against chemical-induced skin cancer.
2012 Oct 4
Patents

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Oral
In Vitro Use Guide
Dicoumarol inhibits rat liver microsomal vitamin K epoxide reductase with IC50=2 uM and cytosolic DT-diaphorase with IC50=0.05 uM.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:06:24 UTC 2023
Edited
by admin
on Fri Dec 15 15:06:24 UTC 2023
Record UNII
7QID3E7BG7
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DICUMAROL
HSDB   MI   ORANGE BOOK   USAN   USP-RS   VANDF  
USAN  
Official Name English
dicoumarol [INN]
Common Name English
3,3'-METHYLENEBIS(4-HYDROXYCOUMARIN)
Systematic Name English
DICUMAROL [ORANGE BOOK]
Common Name English
DICOUMAROLUM [WHO-IP LATIN]
Common Name English
DICOUMAROL [WHO-IP]
Common Name English
DICOUMAROL [MART.]
Common Name English
DICUMAROL [USAN]
Common Name English
DICUMAROL [HSDB]
Common Name English
DICOUMAROL
INN   MART.   WHO-DD   WHO-IP  
INN  
Official Name English
NSC-221570
Code English
DICUMAROL [MI]
Common Name English
2H-1-BENZOPYRAN-2-ONE), 3,3'-METHYLENEBIS(4-HYDROXY-
Systematic Name English
NSC-17860
Code English
DICUMAROL [VANDF]
Common Name English
Dicoumarol [WHO-DD]
Common Name English
NSC-41834
Code English
Classification Tree Code System Code
NCI_THESAURUS C45597
Created by admin on Fri Dec 15 15:06:24 UTC 2023 , Edited by admin on Fri Dec 15 15:06:24 UTC 2023
WHO-VATC QB01AA01
Created by admin on Fri Dec 15 15:06:24 UTC 2023 , Edited by admin on Fri Dec 15 15:06:24 UTC 2023
NCI_THESAURUS C263
Created by admin on Fri Dec 15 15:06:24 UTC 2023 , Edited by admin on Fri Dec 15 15:06:24 UTC 2023
WHO-ATC B01AA01
Created by admin on Fri Dec 15 15:06:24 UTC 2023 , Edited by admin on Fri Dec 15 15:06:24 UTC 2023
Code System Code Type Description
EVMPD
SUB07101MIG
Created by admin on Fri Dec 15 15:06:24 UTC 2023 , Edited by admin on Fri Dec 15 15:06:24 UTC 2023
PRIMARY
DRUG BANK
DB00266
Created by admin on Fri Dec 15 15:06:24 UTC 2023 , Edited by admin on Fri Dec 15 15:06:24 UTC 2023
PRIMARY
NSC
17860
Created by admin on Fri Dec 15 15:06:24 UTC 2023 , Edited by admin on Fri Dec 15 15:06:24 UTC 2023
PRIMARY
HSDB
3223
Created by admin on Fri Dec 15 15:06:24 UTC 2023 , Edited by admin on Fri Dec 15 15:06:24 UTC 2023
PRIMARY
WIKIPEDIA
DICOUMAROL
Created by admin on Fri Dec 15 15:06:24 UTC 2023 , Edited by admin on Fri Dec 15 15:06:24 UTC 2023
PRIMARY
CHEBI
4513
Created by admin on Fri Dec 15 15:06:24 UTC 2023 , Edited by admin on Fri Dec 15 15:06:24 UTC 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
DICUMAROL
Created by admin on Fri Dec 15 15:06:24 UTC 2023 , Edited by admin on Fri Dec 15 15:06:24 UTC 2023
PRIMARY Description: A white or creamy white, crystalline powder; odour, characteristic, faint.Solubility: Practically insoluble in water, ethanol (~750 g/l) TS and ether R.Category: Anticoagulant.Storage: Dicoumarol should be kept in a well-closed container, protected from light.Definition: Dicoumarol contains not less than 98.5% and not more than 101.0% of C19H12O6, calculated with reference to the dried substance.
FDA UNII
7QID3E7BG7
Created by admin on Fri Dec 15 15:06:24 UTC 2023 , Edited by admin on Fri Dec 15 15:06:24 UTC 2023
PRIMARY
MESH
D001728
Created by admin on Fri Dec 15 15:06:24 UTC 2023 , Edited by admin on Fri Dec 15 15:06:24 UTC 2023
PRIMARY
NSC
221570
Created by admin on Fri Dec 15 15:06:24 UTC 2023 , Edited by admin on Fri Dec 15 15:06:24 UTC 2023
PRIMARY
PUBCHEM
54676038
Created by admin on Fri Dec 15 15:06:24 UTC 2023 , Edited by admin on Fri Dec 15 15:06:24 UTC 2023
PRIMARY
SMS_ID
100000082921
Created by admin on Fri Dec 15 15:06:24 UTC 2023 , Edited by admin on Fri Dec 15 15:06:24 UTC 2023
PRIMARY
IUPHAR
6808
Created by admin on Fri Dec 15 15:06:24 UTC 2023 , Edited by admin on Fri Dec 15 15:06:24 UTC 2023
PRIMARY
ALANWOOD
dicoumarol
Created by admin on Fri Dec 15 15:06:24 UTC 2023 , Edited by admin on Fri Dec 15 15:06:24 UTC 2023
PRIMARY
INN
2897
Created by admin on Fri Dec 15 15:06:24 UTC 2023 , Edited by admin on Fri Dec 15 15:06:24 UTC 2023
PRIMARY
ECHA (EC/EINECS)
200-632-9
Created by admin on Fri Dec 15 15:06:24 UTC 2023 , Edited by admin on Fri Dec 15 15:06:24 UTC 2023
PRIMARY
RXCUI
1598
Created by admin on Fri Dec 15 15:06:24 UTC 2023 , Edited by admin on Fri Dec 15 15:06:24 UTC 2023
PRIMARY RxNorm
ChEMBL
CHEMBL1466
Created by admin on Fri Dec 15 15:06:24 UTC 2023 , Edited by admin on Fri Dec 15 15:06:24 UTC 2023
PRIMARY
NSC
41834
Created by admin on Fri Dec 15 15:06:24 UTC 2023 , Edited by admin on Fri Dec 15 15:06:24 UTC 2023
PRIMARY
NCI_THESAURUS
C310
Created by admin on Fri Dec 15 15:06:24 UTC 2023 , Edited by admin on Fri Dec 15 15:06:24 UTC 2023
PRIMARY
CAS
66-76-2
Created by admin on Fri Dec 15 15:06:24 UTC 2023 , Edited by admin on Fri Dec 15 15:06:24 UTC 2023
PRIMARY
DRUG CENTRAL
867
Created by admin on Fri Dec 15 15:06:24 UTC 2023 , Edited by admin on Fri Dec 15 15:06:24 UTC 2023
PRIMARY
MERCK INDEX
m4370
Created by admin on Fri Dec 15 15:06:24 UTC 2023 , Edited by admin on Fri Dec 15 15:06:24 UTC 2023
PRIMARY Merck Index
EPA CompTox
DTXSID8021729
Created by admin on Fri Dec 15 15:06:24 UTC 2023 , Edited by admin on Fri Dec 15 15:06:24 UTC 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY